CAPR

Capricor Therapeutics Inc

• Simply Wall St·2d ago

  How Investors May Respond To Capricor Therapeutics (CAPR) Deramiocel Regulatory Uncertainty After Wider Q1 Loss

• PUBT·2d ago

  Capricor publishes investor presentation on deramiocel Duchenne muscular dystrophy program

• TipRanks·4d ago

  Capricor’s Earnings Call: Deramiocel Drives High-Stakes Pivot

• TipRanks·05/15 06:01

  Capricor Faces Revenue Risk as Dependence on Nippon Shinyaku Puts Deramiocel Commercialization in Jeopardy

• TipRanks·05/15 02:55

  Capricor Therapeutics price target lowered to $38 from $43 at Roth Capital

• TipRanks·05/15 02:35

  Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)

• TipRanks·05/14 11:42

  Wall Street Analysts Are Bullish on Top Healthcare Picks

• Simply Wall St·05/14 06:47

  Assessing Capricor Therapeutics (CAPR) Valuation After Strong Multi Year Gains And Recent Share Price Pullback

• TipRanks·05/13 12:27

  Cantor Fitzgerald Reaffirms Their Buy Rating on Capricor Therapeutics (CAPR)

• TipRanks·05/13 11:40

  Analysts Are Bullish on These Healthcare Stocks: AnaptysBio (ANAB), Legend Biotech (LEGN)

• Dow Jones·05/13 11:18

  Capricor Therapeutics Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

• Benzinga·05/13 11:08

  HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $60 Price Target

• TipRanks·05/13 10:35

  Analyst Reiterates Buy on Capricor Ahead of Key 2026 PDUFA, Maintains $60 Price Target

• Seeking Alpha·05/13 02:51

  Capricor outlines deramiocel PDUFA date of August 22, 2026 while targeting 2,000 to 2,500 patients per year manufacturing capacity

• Benzinga·05/12 21:27

  Capricor Therapeutics Q1 2026 Earnings Call Transcript